VRDN SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWViridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Nov 9, 2026

8-K

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Nov 4, 2026

8-K

Viridian Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Commercial Launch of Lumvoa™

Aug 6, 2026

8-K

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for Thyroid Eye Disease

Jun 26, 2026

8-K

Viridian Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 3, 2026

8-K

Viridian Therapeutics Completes Full Repayment and Termination of Loan Agreement

May 28, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

May 8, 2026

424B5

REGISTERED OFFERING

May 8, 2026

424B5

FIXED PRICE OFFERING - CONVERTIBLE NOTES | Offering amount: $150,000,000 | Bank: Jefferies, Leerink Partners, Goldman Sachs & Co. LLC

May 5, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $100,000,000 | Bank: Jefferies

May 5, 2026

424B5

REGISTERED OFFERING

Oct 22, 2025

424B5

PENDING FIXED PRICE OFFERING

Oct 21, 2025

Registrations

TYPE

HEADLINE

FILED AT

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

May 7, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

May 7, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

May 5, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-3ASR

September 2025 SHELF & ATM

Sep 5, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 17, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 10, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Tousignant Jennifer (Reporting)

Aug 20, 2026

SCHEDULE 13G

Point72 Asset Management, L.P. (Filed by)

Aug 20, 2026

144

Form 144 - Report of proposed sale of securities

Aug 19, 2026

Tripuraneni Radhika (Reporting)

Aug 18, 2026

SCHEDULE 13G/A

Paradigm Biocapital Advisors LP (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Kynam Capital Management, LP (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 18, 2021

CORRESP

Form CORRESP - Correspondence

Nov 15, 2021

LETTER

Form UPLOAD - SEC-generated letter

Nov 10, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 23, 2020

LETTER

Form UPLOAD - SEC-generated letter

Dec 21, 2020

CORRESP

Form CORRESP - Correspondence

Dec 21, 2020

Viridian Therapeutics, Inc. VRDN · SEC Filings